Investors

Lorem ipsum

Lorem ipsum

Alta Life Sciences is a leading venture capital firm located in Barcelona. Alta LS is stage agnostic and invests in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health. Its geographical focus is mainly Spain, although it can invest elsewhere. The team is formed by experienced life science professionals from the US and Spain.

Asabys Partners is a venture capital firm from Barcelona investing across the board in human healthcare. We are active in the health-tech and biopharma industries and aim to invest in Spain and abroad in highly innovative and transformative technologies. We are motivated by the idea of pushing the boundaries of science and medicine. We do this through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry. We have an entrepreneurial spirit and seek to be involved in the building and management of our companies. Not just investors, we consider ourselves as partners and collaborators to our portfolio companies.

AurorA Science is the result of the partnership between the technology transfer company AurorA-TT and two strategic industrial partners and investors, Rottapharm Biotech and Italfarmaco, who share in-house R&D facilities and expertise to support the development of portfolio companies and create the ideal conditions for partnering with bio-pharma companies.

Investment size will vary in a range of €1 to 5M per deal to support the final pre-clinical activities and the early clinical developments.

Lorem ipsum

Biocrew Life Science is a company specialized in strategic orientation processes and the search for private financing for companies in the life sciences and technology sector.

Biocrew life science evaluates invertible projects and performs technical analysis of investment options for investors interested in the health sector.

BME Growth is the market for BME’s SMEs. It is a platform that allows growing small and medium-sized companies to access the capital markets.

At this moment, 129 companies are listed in BME Growth who have raised more than € 5,662 million since its creation.

During the last years, the trading volume of companies in BME Growth has increased by 307%, which represents a compound annual rate of 42.05%, reaching € 1,000 million in 2021.

Entorno Pre Mercado is a special ecosystem created by BME with investors and market professionals for training and networking for those companies who are interested in financing growth via stock markets.

https://www.bmegrowth.es/ing/Home.aspx

Clave Capital is a venture capital firm, focused in tech transfer projects mainly in Spain. We manage currently several funds in investment process with a total volume of more than 30 million euros to invest in different sectors, one of which is Health, counting on not only biotech projects but also and more precisely, Applied Technologies Spinoffs/Startups referred to Medical Devices, mHealth, e-Health…

Our purpose is to invest after the Proof of Concept (TRLs 4-9), in dealflow coming from Universities, Research Centers, or other origins, in a very early stage even taking part in the settlement of the companies (or during the first years) and supporting the startups generating value, not only from a financial or legal perspective but also in fulfilling their strategic goals, thanks to our background investing in Health and also to the involvement of some of our Limited Partners, who are already players in the sector.

Clave Capital was launched in 2002 in Pamplona (North of Spain) where we have our Headquarters. We currently have also branch offices in Valladolid and Valencia and we have managed during this 15 years more than a 100MM€.

Euronext is the leading European stock exchange with an unparallel reach across the continent with presence in 10 countries, +1400 listed companies and an active base of institutional investors from more than 50 countries. Euronext represents a unique platform for Tech companies with more than 500 listed companies, of which ca.110 are in the Life Science segment.

.

.

Fund+ is a Belgian venture capital firm that invests in innovative European Life Sciences companies developing drugs, medical devices and diagnostics, with a strong focus on patient-centric approaches and major unmet medical needs. With over €200M in assets under management, Fund+ has built a strong track record since 2015, investing in 13 portfolio companies with two major exits.  The fund is managed by a specialist team of seasoned life sciences professionals with healthcare industry, corporate finance and strategy consulting experience, supporting companies throughout their growth cycle.  The company aims to maintain a leading position in the Life Sciences sector, creating sustainable value for its shareholders and a tangible impact on society.  www.fundplus.be

GENESIS Ventures is a tech transfer fund sized in2,5 M€ and managed by GENESIS Biomed, that invests in early stage research projects in the biomedical field, with the aim to accelerate their development and reach key value milestones to found the company and attract a first round of investment from other venture funds. The average ticket ranges from 25 to 100k. In our portfolio we have 12 invested companies: ABLE Human Motion, ADmit Therapeutics, CreatSens Health, Aortyx, Droplite, Mowoot, ELEM Bio, two pre-founded projects at IRYCIS and VHIR, NeuroHeal, Quality Pharma Medtech and Limnopharma.

Lorem ipsum

Invivo Capital Partners manages Invivo Ventures, a VC fund that has achieved a first closing of 40M€. It is focused on investing in early-stage companies in the healthcare sector: biotech, medtech, IVD and e-health projects. Our average ticket per company is around 0,5M€ and 2M€ (pre-seed and seed series) with the capacity to further invest through follow-ons in later stages of the best performing portfolio companies depending on the project and financial needs. Geographic focus is mainly Spain but other European companies are considered.

The team also manages Healthequity, SCR. since 2013, a VC fund also focused on the healthcare sector, which has already finished its investment period.

IPF Partners is a leading alternative financing provider focused on the healthcare sector. IPF Partners invests directly in emerging commercial stage pharma/biotech, medtech, diagnostics and IT healthcare companies.

IPF Partners provides customised low- to non-dilutive debt and equity financing to market leading healthcare companies.

The focus is on innovating products at commercial stage with a high potential in attractive markets. Typical deal size ranges from €5-25m+ over a 3- to 6-year duration.

Kaudal is a private equity financial structurer that believes in R&D and technology as fundamental drivers for the well-being and growth of our society. Our aim is to attract new investment that will help boost the development of innovative companies in Spain, strengthen the Spanish R&D ecosystem and facilitate the transfer of knowledge to the business world.

We are leaders in private financial structuring of R&D operations in Spain. We identify research and development projects and provide them with the funding necessary to be carried out. Since 2017, we have supported more than 70 projects for an investment volume of 100 million euros.

Keensight Capital is a European Growth Buyout investor with deep expertise in Healthcare and IT partnering with the management teams of fast growing and profitable companies providing capital, strategic guidance and operational support.

For 20 years, Keensight Capital’s team has leveraged their knowledge of investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €15 million to €250 million

Lorem ipsum

M Ventures is the corporate Venture Capital arm of Merck KgaA, Darmstadt Germany and takes an active role in company creation and investment.

M Ventures invests in innovative, early stage technology and biopharmaceutical companies with the potential to significantly impact Merck‘s business areas. The two core investment areas are technology and biotechnology, the technology mandate focuses on advanced chemistries, quantum computing, frontier tech and sustainability. The biotechnology mandate focuses on therapeutics and enabling technologies. Key areas of interest for therapeutics include immunology, oncology, immune-oncology and fertility.

Omnes is a leading Paris-based European investor in private equity and infrastructure. With €4 billion of assets under management, Omnes provides SMEs with the capital needed to finance growth. The firm has dedicated investment teams across three key areas: Venture Capital, Buyout & Growth Capital and Infrastructure. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Novaled, Biovex, arGEN-X, Themis Bioscience and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors.

www.omnescapital.com

For almost two decades, XesGalicia has managed risk capital entities to support the growth of Galician companies. In this sense, our priorities focus on promoting the economic and industrial development and consolidation of Galicia, for which we have several financial instruments oriented to each type of company.

http://www.xesgalicia.gal/

Ysios Capital is a leading Spanish independent venture capital firm that provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies.

Founded in 2008, Ysios Capital manages c.a. €350 M through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies